Cover Image
市場調查報告書

生物科技的表觀遺傳學市場:成長,趨勢,預測(2017年∼2022年)

Global Epigenetics Market in Biotechnology Growth, Trends and Forecasts (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 390672
出版日期 內容資訊 英文 203 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物科技的表觀遺傳學市場:成長,趨勢,預測(2017年∼2022年) Global Epigenetics Market in Biotechnology Growth, Trends and Forecasts (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 203 Pages
簡介

表觀遺傳學市場2012年價值12億美元,至2018年預計以26.85%的年複合成長率大幅成長到49億2,000萬美元。

本報告提供生物科技的表觀遺傳學市場相關調查,市場概要,各作用/技術、用途、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 報告的說明
  • 調查方法
  • 相關利益者

第2章 摘要整理

  • 主要的觀察
  • 市場概況

第3章 市場概要

  • 市場決策
    • 簡介
  • 市場區隔
    • 作用/技術
    • 用途
    • 各地區
  • 市場成長要素
    • 癌症患者的全球性增加
    • 廣泛的用途
    • 投資、資金的增加
  • 市場阻礙因素
    • 償付計劃的缺乏
    • 預測標記的缺乏

第4章 市場區隔:各作用/技術

  • DNA甲基化
  • 組蛋白修正
  • RNA干擾

第5章 市場區隔:各地區

  • 北美
  • 歐洲
  • 其他地區
  • 亞太地區

第6章 競爭情形

  • 簡介
  • 合併、收購
  • 事業擴張
  • 新產品的銷售
  • 合作

第7章 企業簡介

  • 4SC
  • Cellgene
  • Cellcentric
  • Covaris Inc
  • Epiontis
  • Epitherapeutics
  • Epizyme
  • Karus Therapeutics
  • Merck Millipore
  • Ribimed Biotechnologies

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

Epigenetics is the study of changes in gene expression caused by certain base pairs in DNA, or RNA, being "turned off" or "turned on" again, through chemical reactions. In biology, and specifically genetics, epigenetics is mostly the study of heritable changes that are not caused by changes in the DNA sequence; to a lesser extent, epigenetics also describes the study of stable, long-term alterations in the transcriptional potential of a cell that are not necessarily heritable. The term also refers to the changes themselves: functionally relevant changes to the genome that do not involve a change in the nucleotide sequence. Examples of mechanisms that produce such changes are DNA methylation and histone modification, each of which alters how genes are expressed without altering the underlying DNA sequence.

The epigenetics market valued as a 1.2 billion USD market in 2012 is expected to show a very high growth and is expected to become a 4.92 billion USD market by 2018 showing a CAGR as high as 26.85%

The epigenetics market is basically segmented into three categories mainly on the basis of technique, applications and geography. The mechanism sector can be segmented into three different categories mainly DNA Methylation, RNA Interference and Histone Modifications. On the basis of geography the market is divided into North America, Europe, APAC and the rest of the world.

The major drivers for the growth of this market are the high incidence of cancer rate, wide range of applications it has and the increasing investment and funds to this field of science. The major challenges faced by epigenetics are the lack of reimbursement policy and the lack of predictive markers.

The major players in this field are 4SC, Celgene, Cellcentric, Covaris, Epiontis, Epitherapeutics, Epizyme and Merck Millipore.

Table of Contents

1.INTRODUCTION

  • 1.1 Report Description
  • 1.2 Research Methodology
  • 1.3 Stakeholders

2. EXECUTIVE SUMMARY

  • 2.1 Key Findings
  • 2.2 Market Overview

3. MARKET OVERVIEW

  • 3.1 Market Defenition
    • 3.1.1 Introduction
  • 3.2 Market Segmentation
    • 3.2.1 Technology
    • 3.2.2 Applications
    • 3.2.3 Geography
  • 3.3 Market Drivers
    • 3.3.1 Global Cancer
    • 3.3.2 Wide range of applications
    • 3.3.3 Increasing investments & funds
  • 3.4 Market Restraints
    • 3.4.1 Lack of Reimbursment plans
    • 3.4.2 Lack of predictive markers

4. GLOBAL MARKETS: SEGMENTATION BY MECHANISMS/TECHNOLOGY

  • 4.1 DNA Methylation
  • 4.2 Histone Modifications
  • 4.3 RNA Interference

5. GLOBAL MARKETS: SEGMENTATION BY GEOGRAPHY

  • 5.1 North America
  • 5.2 Europe
  • 5.3 Rest of the World
  • 5.4 APAC

6. COMPETITVE LANDSCAPE

  • 6.1 Introduction
  • 6.2 Mergers & Acquisitions
  • 6.3 Expansions
  • 6.4 New Product Launch
  • 6.5 Collaborations

7. COMPANY PROFILES

  • 7.1 4SC
  • 7.2 Cellgene
  • 7.3 Cellcentric
  • 7.4 Covaris Inc
  • 7.5 Epiontis
  • 7.6 Epitherapeutics
  • 7.7 Epizyme
  • 7.8 Karus Therapeutics
  • 7.9 Merck Millipore
  • 7.10 Ribimed Biotechnologies

8. Appendix

Back to Top